Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Cariprazine, a potent dopamine D(3) and D(2) receptor partial agonist antipsychotic with preferential binding to D(3) receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int Clin Psychopharmacol
Päätekijät: Earley, Willie, Durgam, Suresh, Lu, Kaifeng, Laszlovszky, István, Debelle, Marc, Kane, John M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams And Wilkins 2017
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5625952/
https://ncbi.nlm.nih.gov/pubmed/28692485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000187
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia